Aura Biosciences Files 8-K on Financials and Operations

Ticker: AURA · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001501796

Aura Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyAura Biosciences, INC. (AURA)
Form Type8-K
Filed DateMar 30, 2026
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: financial-results, operations, sec-filing

TL;DR

Aura Biosciences dropped an 8-K on 3/30/26 covering financials and other key events.

AI Summary

Aura Biosciences, Inc. filed an 8-K on March 30, 2026, reporting on its results of operations and financial condition, as well as other events. The filing includes various exhibits, such as financial statements and graphics, related to the company's performance.

Why It Matters

This 8-K filing provides investors with crucial updates on Aura Biosciences' financial health and operational status, enabling informed investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant news that impacts stock price, requiring careful review.

Key Players & Entities

FAQ

What specific financial results are detailed in this 8-K filing?

The filing indicates Item 2.02 (Results of Operations and Financial Condition) is covered, but the specific financial figures are not detailed in the provided text, only that it is reported.

What other types of events are reported in this 8-K?

The filing also covers Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).

When was this 8-K filing accepted by the SEC?

The filing was accepted on March 30, 2026, at 07:05:19.

What is the purpose of the numerous graphic files listed as exhibits?

The graphic files (img28679202_0.gif, aura-ex99_2s1.jpg, etc.) are likely visual aids or presentations accompanying the financial and operational information in the 8-K.

Does this filing contain preliminary or final financial statements?

The filing lists Item 9.01 (Financial Statements and Exhibits), suggesting that financial statements are included, but their preliminary or final nature is not specified in the provided text.

Filing Stats: 1,288 words · 5 min read · ~4 pages · Grade level 15.3 · Accepted 2026-03-30 07:05:19

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 30, 2026, Aura Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On March 30, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts, and others. A copy of the corporate presentation is filed as Exhibit 99.2 for purposes of Section 18 of the Exchange Act. Cautionary Note Regarding Forward Looking Statements

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No . Description 99.1 Press Release Dated March 30, 2026. 99.2 Corporate Presentation of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: March 30, 2026 By: /s/ Elisabet de los Pinos Elisabet de los Pinos President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing